FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Boothwyn Pharmacy Semaglutide Recall

Semaglutide, 2

Boothwyn Pharmacy LLC · Kennett Square, PA

Risk level
Class II
Reported by FDA
Sep 10, 2025
Recall ID
D-0609-2025
Check your lot numberHow we source this data

Summary

Boothwyn Pharmacy recalled Semaglutide starting Jul 9, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0609-2025 on Sep 10, 2025. Reason: Subpotent Drug. Status: Ongoing.

Why it was recalled

Subpotent Drug

Product description

Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy

Lot numbers, UPCs & expiration codes

03202025@2, 03202025@3 and 03202025@4 BUD 07/18/2025

Where it was sold

U.S. Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0609-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jul 9, 2025
FDA report date
Sep 10, 2025
Quantity
648 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Boothwyn Pharmacy LLC

Original FDA data

Every field from FDA enforcement report D-0609-2025, exactly as published.

Show all FDA fields
City
Kennett Square
State
PA
Status
Ongoing
Country
United States
Event ID
97202
Address
221 Gale Ln
Code information
03202025@2, 03202025@3 and 03202025@4 BUD 07/18/2025
Postal code
19348
Report date
Sep 10, 2025
Product type
Drugs
Recall number
D-0609-2025
Classification
Class II
Recalling firm
Boothwyn Pharmacy LLC
Product quantity
648 vials
Reason for recall
Subpotent Drug
Voluntary / mandated
Voluntary: Firm initiated
Product description
Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
Distribution pattern
U.S. Nationwide
Recall initiation date
Jul 9, 2025
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Aug 29, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0609-2025, published Sep 10, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls